JP2014097072A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014097072A5 JP2014097072A5 JP2014032700A JP2014032700A JP2014097072A5 JP 2014097072 A5 JP2014097072 A5 JP 2014097072A5 JP 2014032700 A JP2014032700 A JP 2014032700A JP 2014032700 A JP2014032700 A JP 2014032700A JP 2014097072 A5 JP2014097072 A5 JP 2014097072A5
- Authority
- JP
- Japan
- Prior art keywords
- strand
- double
- nucleotides
- overhang
- airna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 430
- 125000003729 nucleotide group Chemical group 0.000 claims description 298
- 239000002773 nucleotide Substances 0.000 claims description 243
- 108020004459 Small interfering RNA Proteins 0.000 claims description 222
- 210000004027 cell Anatomy 0.000 claims description 134
- 230000030279 gene silencing Effects 0.000 claims description 130
- 238000012226 gene silencing method Methods 0.000 claims description 108
- 230000000692 anti-sense effect Effects 0.000 claims description 96
- 108091081021 Sense strand Proteins 0.000 claims description 63
- 108020004999 messenger RNA Proteins 0.000 claims description 53
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 47
- 210000004962 mammalian cell Anatomy 0.000 claims description 26
- 230000004048 modification Effects 0.000 claims description 25
- 238000012986 modification Methods 0.000 claims description 25
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 19
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 108091028664 Ribonucleotide Proteins 0.000 claims description 11
- 239000002336 ribonucleotide Substances 0.000 claims description 11
- 230000009467 reduction Effects 0.000 claims description 10
- 241000271566 Aves Species 0.000 claims description 9
- 230000002452 interceptive effect Effects 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 125000005642 phosphothioate group Chemical group 0.000 claims description 7
- 229930010555 Inosine Natural products 0.000 claims description 6
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 229960003786 inosine Drugs 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 description 218
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 210
- 108090000623 proteins and genes Proteins 0.000 description 118
- 238000000034 method Methods 0.000 description 77
- 108060000903 Beta-catenin Proteins 0.000 description 75
- 102000015735 Beta-catenin Human genes 0.000 description 75
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 68
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 68
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 58
- 230000009368 gene silencing by RNA Effects 0.000 description 58
- 239000002585 base Substances 0.000 description 53
- 230000000295 complement effect Effects 0.000 description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 47
- 230000014509 gene expression Effects 0.000 description 40
- 206010028980 Neoplasm Diseases 0.000 description 33
- 201000010099 disease Diseases 0.000 description 33
- -1 EBRB2 Proteins 0.000 description 30
- 108700011259 MicroRNAs Proteins 0.000 description 30
- 101150084233 ago2 gene Proteins 0.000 description 30
- 239000008194 pharmaceutical composition Substances 0.000 description 29
- 239000013604 expression vector Substances 0.000 description 27
- 238000011282 treatment Methods 0.000 description 27
- 238000001890 transfection Methods 0.000 description 26
- 150000007523 nucleic acids Chemical class 0.000 description 24
- 102000039446 nucleic acids Human genes 0.000 description 23
- 108020004707 nucleic acids Proteins 0.000 description 23
- 238000012384 transportation and delivery Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 101150099493 STAT3 gene Proteins 0.000 description 20
- 238000003776 cleavage reaction Methods 0.000 description 20
- 230000001404 mediated effect Effects 0.000 description 20
- 230000007017 scission Effects 0.000 description 20
- 230000008685 targeting Effects 0.000 description 20
- 239000000203 mixture Substances 0.000 description 17
- 238000001262 western blot Methods 0.000 description 16
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 15
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 15
- 238000011529 RT qPCR Methods 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 108091034117 Oligonucleotide Proteins 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 14
- 238000011160 research Methods 0.000 description 14
- 108010085238 Actins Proteins 0.000 description 13
- 239000003937 drug carrier Substances 0.000 description 13
- 229920000642 polymer Polymers 0.000 description 13
- 102000007469 Actins Human genes 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 230000007246 mechanism Effects 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 11
- 206010009944 Colon cancer Diseases 0.000 description 11
- 108050006400 Cyclin Proteins 0.000 description 11
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 11
- 108010002687 Survivin Proteins 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 208000029742 colonic neoplasm Diseases 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 238000003757 reverse transcription PCR Methods 0.000 description 11
- 230000002194 synthesizing effect Effects 0.000 description 11
- 102100031334 Elongation factor 2 Human genes 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 108010077519 Peptide Elongation Factor 2 Proteins 0.000 description 10
- 239000000969 carrier Substances 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 10
- 239000002502 liposome Substances 0.000 description 10
- 239000006166 lysate Substances 0.000 description 10
- 239000002679 microRNA Substances 0.000 description 10
- 239000002105 nanoparticle Substances 0.000 description 10
- 230000003389 potentiating effect Effects 0.000 description 10
- 230000002285 radioactive effect Effects 0.000 description 10
- 108020005544 Antisense RNA Proteins 0.000 description 9
- 208000035473 Communicable disease Diseases 0.000 description 9
- 239000003184 complementary RNA Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000010468 interferon response Effects 0.000 description 9
- 238000011068 loading method Methods 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 8
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 8
- 101150071831 RPS6KA1 gene Proteins 0.000 description 8
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 8
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 101150063226 parp-1 gene Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000011200 topical administration Methods 0.000 description 8
- 238000000636 Northern blotting Methods 0.000 description 7
- 108700005077 Viral Genes Proteins 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 230000010354 integration Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 230000004614 tumor growth Effects 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 6
- 108091023037 Aptamer Proteins 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 108091032955 Bacterial small RNA Proteins 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 description 6
- 101000876829 Homo sapiens Protein C-ets-1 Proteins 0.000 description 6
- 102100034343 Integrase Human genes 0.000 description 6
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 6
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 6
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 102100035251 Protein C-ets-1 Human genes 0.000 description 6
- 102000001253 Protein Kinase Human genes 0.000 description 6
- 102000006382 Ribonucleases Human genes 0.000 description 6
- 108010083644 Ribonucleases Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000007385 chemical modification Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 208000016097 disease of metabolism Diseases 0.000 description 6
- 238000003197 gene knockdown Methods 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 208000030159 metabolic disease Diseases 0.000 description 6
- 108091070501 miRNA Proteins 0.000 description 6
- 239000007908 nanoemulsion Substances 0.000 description 6
- 230000009437 off-target effect Effects 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 230000002688 persistence Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 235000019833 protease Nutrition 0.000 description 6
- 108060006633 protein kinase Proteins 0.000 description 6
- 208000023504 respiratory system disease Diseases 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 208000017520 skin disease Diseases 0.000 description 6
- 208000017701 Endocrine disease Diseases 0.000 description 5
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 5
- 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 5
- 101000800539 Mus musculus Translationally-controlled tumor protein Proteins 0.000 description 5
- 101150081841 NBN gene Proteins 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 5
- 241000269435 Rana <genus> Species 0.000 description 5
- 208000025747 Rheumatic disease Diseases 0.000 description 5
- 101000781972 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein wos2 Proteins 0.000 description 5
- 108091027967 Small hairpin RNA Proteins 0.000 description 5
- 101001009610 Toxoplasma gondii Dense granule protein 5 Proteins 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 208000017169 kidney disease Diseases 0.000 description 5
- 238000001638 lipofection Methods 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 208000015122 neurodegenerative disease Diseases 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000002085 persistent effect Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 102100024026 Transcription factor E2F1 Human genes 0.000 description 4
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 4
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 101150042537 dld1 gene Proteins 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012133 immunoprecipitate Substances 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 244000000010 microbial pathogen Species 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 3
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 3
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 3
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 239000004382 Amylase Substances 0.000 description 3
- 108010065511 Amylases Proteins 0.000 description 3
- 102000013142 Amylases Human genes 0.000 description 3
- 208000031295 Animal disease Diseases 0.000 description 3
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 3
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 3
- 108091012583 BCL2 Proteins 0.000 description 3
- 108700020463 BRCA1 Proteins 0.000 description 3
- 102000036365 BRCA1 Human genes 0.000 description 3
- 101150072950 BRCA1 gene Proteins 0.000 description 3
- 108700020462 BRCA2 Proteins 0.000 description 3
- 102000052609 BRCA2 Human genes 0.000 description 3
- 102100026189 Beta-galactosidase Human genes 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101150008921 Brca2 gene Proteins 0.000 description 3
- 108090000489 Carboxy-Lyases Proteins 0.000 description 3
- 102100035882 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 108010059892 Cellulase Proteins 0.000 description 3
- 108010076010 Cystathionine beta-lyase Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108700029231 Developmental Genes Proteins 0.000 description 3
- 102100035813 E3 ubiquitin-protein ligase CBL Human genes 0.000 description 3
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 3
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 3
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 3
- 102100034169 Eukaryotic translation initiation factor 2-alpha kinase 1 Human genes 0.000 description 3
- 101710196289 Eukaryotic translation initiation factor 2-alpha kinase 1 Proteins 0.000 description 3
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 3
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 3
- 102100029974 GTPase HRas Human genes 0.000 description 3
- 102100030708 GTPase KRas Human genes 0.000 description 3
- 102100039788 GTPase NRas Human genes 0.000 description 3
- 108091006109 GTPases Proteins 0.000 description 3
- 108010093031 Galactosidases Proteins 0.000 description 3
- 102000002464 Galactosidases Human genes 0.000 description 3
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 3
- 108010015776 Glucose oxidase Proteins 0.000 description 3
- 239000004366 Glucose oxidase Substances 0.000 description 3
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 description 3
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 3
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 3
- 101000980756 Homo sapiens G1/S-specific cyclin-D1 Proteins 0.000 description 3
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 3
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 3
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 3
- 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 description 3
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 description 3
- 101000954986 Homo sapiens Merlin Proteins 0.000 description 3
- 101000585703 Homo sapiens Protein L-Myc Proteins 0.000 description 3
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 3
- 101000861454 Homo sapiens Protein c-Fos Proteins 0.000 description 3
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 3
- 101000742859 Homo sapiens Retinoblastoma-associated protein Proteins 0.000 description 3
- 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 3
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 3
- 101000891113 Homo sapiens T-cell acute lymphocytic leukemia protein 1 Proteins 0.000 description 3
- 101000800488 Homo sapiens T-cell leukemia homeobox protein 1 Proteins 0.000 description 3
- 101000837626 Homo sapiens Thyroid hormone receptor alpha Proteins 0.000 description 3
- 101000813738 Homo sapiens Transcription factor ETV6 Proteins 0.000 description 3
- 101000636213 Homo sapiens Transcriptional activator Myb Proteins 0.000 description 3
- 101000912503 Homo sapiens Tyrosine-protein kinase Fgr Proteins 0.000 description 3
- 101001022129 Homo sapiens Tyrosine-protein kinase Fyn Proteins 0.000 description 3
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 3
- 101001054878 Homo sapiens Tyrosine-protein kinase Lyn Proteins 0.000 description 3
- 108010061833 Integrases Proteins 0.000 description 3
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 3
- 101710089751 Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000004195 Isomerases Human genes 0.000 description 3
- 108090000769 Isomerases Proteins 0.000 description 3
- 108010059881 Lactase Proteins 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 3
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 3
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 3
- 108010085793 Neurofibromin 1 Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 108010064785 Phospholipases Proteins 0.000 description 3
- 102000015439 Phospholipases Human genes 0.000 description 3
- 108010073135 Phosphorylases Proteins 0.000 description 3
- 102000009097 Phosphorylases Human genes 0.000 description 3
- 108010059820 Polygalacturonase Proteins 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 102100030128 Protein L-Myc Human genes 0.000 description 3
- 102100026375 Protein PML Human genes 0.000 description 3
- 102100027584 Protein c-Fos Human genes 0.000 description 3
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 102000018120 Recombinases Human genes 0.000 description 3
- 108010091086 Recombinases Proteins 0.000 description 3
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 3
- 101150019443 SMAD4 gene Proteins 0.000 description 3
- 101000702553 Schistosoma mansoni Antigen Sm21.7 Proteins 0.000 description 3
- 101000714192 Schistosoma mansoni Tegument antigen Proteins 0.000 description 3
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 3
- 108700031298 Smad4 Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102100040365 T-cell acute lymphocytic leukemia protein 1 Human genes 0.000 description 3
- 102100033111 T-cell leukemia homeobox protein 1 Human genes 0.000 description 3
- 102100028702 Thyroid hormone receptor alpha Human genes 0.000 description 3
- 101710183280 Topoisomerase Proteins 0.000 description 3
- 102100039580 Transcription factor ETV6 Human genes 0.000 description 3
- 102100030780 Transcriptional activator Myb Human genes 0.000 description 3
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 3
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 3
- 102100026150 Tyrosine-protein kinase Fgr Human genes 0.000 description 3
- 102100035221 Tyrosine-protein kinase Fyn Human genes 0.000 description 3
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 3
- 102100026857 Tyrosine-protein kinase Lyn Human genes 0.000 description 3
- 108700020467 WT1 Proteins 0.000 description 3
- 101150084041 WT1 gene Proteins 0.000 description 3
- 108010036419 acyl-(acyl-carrier-protein)desaturase Proteins 0.000 description 3
- 235000019418 amylase Nutrition 0.000 description 3
- 238000011717 athymic nude mouse Methods 0.000 description 3
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940106157 cellulase Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000003596 drug target Substances 0.000 description 3
- 208000030172 endocrine system disease Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006718 epigenetic regulation Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 229940116332 glucose oxidase Drugs 0.000 description 3
- 235000019420 glucose oxidase Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 108010002430 hemicellulase Proteins 0.000 description 3
- 229940059442 hemicellulase Drugs 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000001573 invertase Substances 0.000 description 3
- 235000011073 invertase Nutrition 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 229940116108 lactase Drugs 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 238000010208 microarray analysis Methods 0.000 description 3
- 108020004410 pectinesterase Proteins 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000005556 structure-activity relationship Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- WFPZSXYXPSUOPY-ROYWQJLOSA-N ADP alpha-D-glucoside Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WFPZSXYXPSUOPY-ROYWQJLOSA-N 0.000 description 2
- WFPZSXYXPSUOPY-UHFFFAOYSA-N ADP-mannose Natural products C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COP(O)(=O)OP(O)(=O)OC1OC(CO)C(O)C(O)C1O WFPZSXYXPSUOPY-UHFFFAOYSA-N 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 241000255601 Drosophila melanogaster Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 2
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 2
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 2
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- 108700012912 MYCN Proteins 0.000 description 2
- 101150022024 MYCN gene Proteins 0.000 description 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 2
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000012807 PCR reagent Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 102000001332 SRC Human genes 0.000 description 2
- 108060006706 SRC Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 238000003975 animal breeding Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 108010045569 atelocollagen Proteins 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000037429 base substitution Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 108091007428 primary miRNA Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012447 xenograft mouse model Methods 0.000 description 2
- UIYWFOZZIZEEKJ-XVFCMESISA-N 1-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound F[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 UIYWFOZZIZEEKJ-XVFCMESISA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 101710197633 Actin-1 Proteins 0.000 description 1
- 108090000104 Actin-related protein 3 Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 1
- 102100039239 Amidophosphoribosyltransferase Human genes 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100499346 Caenorhabditis elegans dld-1 gene Proteins 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 108700005443 Microbial Genes Proteins 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 102000010410 Nogo Proteins Human genes 0.000 description 1
- 108010077641 Nogo Proteins Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000012233 TRIzol extraction Methods 0.000 description 1
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000009614 chemical analysis method Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014684 gene silencing by miRNA Effects 0.000 description 1
- 230000037440 gene silencing effect Effects 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical group 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000001743 silencing effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96825707P | 2007-08-27 | 2007-08-27 | |
| US60/968,257 | 2007-08-27 | ||
| US2975308P | 2008-02-19 | 2008-02-19 | |
| US61/029,753 | 2008-02-19 | ||
| US3895408P | 2008-03-24 | 2008-03-24 | |
| US61/038,954 | 2008-03-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010523120A Division JP2010537639A (ja) | 2007-08-27 | 2008-08-27 | 非対称性干渉ｒｎａの組成物およびその使用 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015085681A Division JP2015130885A (ja) | 2007-08-27 | 2015-04-20 | 非対称性干渉ｒｎａの組成物およびその使用 |
| JP2016122512A Division JP6453275B2 (ja) | 2007-08-27 | 2016-06-21 | 非対称性干渉ｒｎａの組成物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014097072A JP2014097072A (ja) | 2014-05-29 |
| JP2014097072A5 true JP2014097072A5 (enExample) | 2015-06-11 |
| JP5986596B2 JP5986596B2 (ja) | 2016-09-06 |
Family
ID=40387778
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010523120A Pending JP2010537639A (ja) | 2007-08-27 | 2008-08-27 | 非対称性干渉ｒｎａの組成物およびその使用 |
| JP2010523121A Pending JP2010537640A (ja) | 2007-08-27 | 2008-08-27 | マイクロｒｎａ模倣剤または阻害剤としての非対称性ｒｎａ二重鎖の組成物 |
| JP2014032700A Active JP5986596B2 (ja) | 2007-08-27 | 2014-02-24 | 非対称性干渉ｒｎａの組成物およびその使用 |
| JP2015085681A Pending JP2015130885A (ja) | 2007-08-27 | 2015-04-20 | 非対称性干渉ｒｎａの組成物およびその使用 |
| JP2016113256A Active JP6236498B2 (ja) | 2007-08-27 | 2016-06-07 | 非対称性干渉ｒｎａの組成物およびその使用 |
| JP2016122512A Active JP6453275B2 (ja) | 2007-08-27 | 2016-06-21 | 非対称性干渉ｒｎａの組成物およびその使用 |
| JP2017091309A Pending JP2017127333A (ja) | 2007-08-27 | 2017-05-01 | 非対称性干渉ｒｎａの組成物およびその使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010523120A Pending JP2010537639A (ja) | 2007-08-27 | 2008-08-27 | 非対称性干渉ｒｎａの組成物およびその使用 |
| JP2010523121A Pending JP2010537640A (ja) | 2007-08-27 | 2008-08-27 | マイクロｒｎａ模倣剤または阻害剤としての非対称性ｒｎａ二重鎖の組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015085681A Pending JP2015130885A (ja) | 2007-08-27 | 2015-04-20 | 非対称性干渉ｒｎａの組成物およびその使用 |
| JP2016113256A Active JP6236498B2 (ja) | 2007-08-27 | 2016-06-07 | 非対称性干渉ｒｎａの組成物およびその使用 |
| JP2016122512A Active JP6453275B2 (ja) | 2007-08-27 | 2016-06-21 | 非対称性干渉ｒｎａの組成物およびその使用 |
| JP2017091309A Pending JP2017127333A (ja) | 2007-08-27 | 2017-05-01 | 非対称性干渉ｒｎａの組成物およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US9328345B2 (enExample) |
| EP (4) | EP3121281B1 (enExample) |
| JP (7) | JP2010537639A (enExample) |
| CN (3) | CN105018492B (enExample) |
| CA (2) | CA2735166C (enExample) |
| DK (1) | DK2193140T3 (enExample) |
| ES (2) | ES2617877T3 (enExample) |
| WO (2) | WO2009029688A2 (enExample) |
Families Citing this family (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008073578A2 (en) | 2006-12-08 | 2008-06-19 | Iowa State University Research Foundation, Inc. | Plant genes involved in nitrate uptake and metabolism |
| EP3121281B1 (en) | 2007-08-27 | 2021-03-31 | 1Globe Health Institute LLC | Compositions of asymmetric interfering rna and uses thereof |
| US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
| KR100949791B1 (ko) * | 2007-12-18 | 2010-03-30 | 이동기 | 오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도 |
| EP2342340A1 (en) | 2008-09-22 | 2011-07-13 | Rxi Pharmaceuticals Corporation | Rna interference in skin indications |
| US20110287026A1 (en) | 2008-09-23 | 2011-11-24 | President And Fellows Of Harvard College | Sirt4 and uses thereof |
| WO2010045384A2 (en) | 2008-10-15 | 2010-04-22 | Somagenics Inc. | Short hairpin rnas for inhibition of gene expression |
| US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
| WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| EP2756845B1 (en) * | 2009-04-03 | 2017-03-15 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA |
| JP6010458B2 (ja) * | 2009-04-03 | 2016-10-19 | ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 非対称二本鎖ｒｎａによる特異的阻害のための、方法および組成物 |
| WO2010141933A1 (en) * | 2009-06-05 | 2010-12-09 | Dicerna Pharmaceuticals, Inc. | Specific inhibition of gene expression by nucleic acid containing a dicer substrate |
| US8871730B2 (en) | 2009-07-13 | 2014-10-28 | Somagenics Inc. | Chemical modification of short small hairpin RNAs for inhibition of gene expression |
| US8796238B2 (en) | 2009-09-17 | 2014-08-05 | Sigma-Aldrich Co. Llc | Short RNA mimetics |
| CN102639700A (zh) | 2009-09-30 | 2012-08-15 | 哈佛大学校长及研究员协会 | 通过调节自噬增强基因产物调节自噬的方法 |
| US20150025122A1 (en) | 2009-10-12 | 2015-01-22 | Larry J. Smith | Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro |
| US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
| KR101237036B1 (ko) * | 2009-11-04 | 2013-02-25 | 성균관대학교산학협력단 | 안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 ｓｉＲＮＡ 구조 및 그 용도 |
| JP2013514277A (ja) * | 2009-12-16 | 2013-04-25 | ザ ユニバーシティ オブ ウェスタン オンタリオ | 糖尿病におけるｍｉＲＮＡに関連する組成物と方法 |
| KR101982126B1 (ko) | 2010-03-08 | 2019-05-27 | 몬산토 테크놀로지 엘엘씨 | 식물에서 유전자 조절을 위한 폴리뉴클레오타이드 분자 |
| US9095504B2 (en) | 2010-03-24 | 2015-08-04 | Rxi Pharmaceuticals Corporation | RNA interference in ocular indications |
| WO2011119852A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering rnai compounds |
| CA2794189C (en) | 2010-03-24 | 2022-01-11 | Rxi Pharmaceuticals Corporation | Rna interference in dermal and fibrotic indications |
| PT2561078T (pt) | 2010-04-23 | 2018-12-03 | Cold Spring Harbor Laboratory | Sharn com uma conceção estrutural inovadora |
| GB201006841D0 (en) * | 2010-04-26 | 2010-06-09 | Thomsen Lars | Method, device and system for targetted cell lysis |
| CN103328633B (zh) * | 2010-10-22 | 2018-07-10 | 成均馆大学校产学协力团 | 诱导rna干扰的核酸分子及其用途 |
| CN101979558B (zh) * | 2010-10-28 | 2015-09-02 | 百奥迈科生物技术有限公司 | 一种靶向乙型肝炎病毒基因的siRNA分子及其应用 |
| WO2012140234A1 (en) | 2011-04-13 | 2012-10-18 | Vib Vzw | Modulation of mirna in diseases with aberrant angiogenesis |
| WO2012149646A1 (en) * | 2011-05-05 | 2012-11-08 | Sunnybrook Research Institute | Mirna inhibitors and their uses |
| ES2632212T3 (es) | 2011-08-04 | 2017-09-11 | Yeda Research And Development Co. Ltd. | miR-135 y composiciones que lo comprenden para el tratamiento de afecciones médicas asociadas con la serotonina |
| US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
| US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
| US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
| BR112014005975A8 (pt) | 2011-09-13 | 2017-09-12 | Monsanto Technology Llc | Método de controle de planta, método de redução de expressão de um gene pds em uma planta, cassete de expressão microbiana, método de fazer um polinucleotídeo, método de identificação de polinucleotídeos, e composições para controle de erva daninha |
| EP2766482B1 (en) * | 2011-10-11 | 2016-12-07 | The Brigham and Women's Hospital, Inc. | Micrornas in neurodegenerative disorders |
| JP6137484B2 (ja) * | 2011-11-02 | 2017-05-31 | 公立大学法人大阪市立大学 | 遺伝子発現抑制用二本鎖核酸分子 |
| WO2013138280A1 (en) * | 2012-03-12 | 2013-09-19 | Eaker Shannon | IMPROVED ENGRAFTMENT POTENTIAL OF EMBRYONIC STEM CELLS AND PLURIPOTENT STEM CELLS USING MICRO RNAs |
| CN108148838B (zh) | 2012-05-22 | 2026-07-31 | 奥利克斯医药有限公司 | 具有细胞内穿透能力的诱导rna干扰的核酸分子及用途 |
| CN104619843B (zh) | 2012-05-24 | 2020-03-06 | A.B.种子有限公司 | 用于使基因表达沉默的组合物和方法 |
| US9663784B2 (en) | 2012-05-26 | 2017-05-30 | Bonac Corporation | Single-stranded nucleic acid molecule for regulating expression of gene having delivering function |
| EP2703498B1 (en) * | 2012-08-29 | 2015-01-14 | Chanel Parfums Beauté | Inhibitors of micro-RNAs for use for preventing and/or attenuating skin ageing |
| US9096853B2 (en) * | 2012-09-24 | 2015-08-04 | U.S. Department Of Veterans Affairs | Modified siRNA molecules incorporating 5-fluoro-2′-deoxyuridine residues to enhance cytotoxicity |
| US9694050B2 (en) | 2012-10-21 | 2017-07-04 | University Of Rochester | THY1 (CD90) as a novel therapy to control adipose tissue accumulation |
| WO2014089121A2 (en) * | 2012-12-03 | 2014-06-12 | Thomas Ichim | Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases |
| ES2873600T3 (es) * | 2013-02-05 | 2021-11-03 | 1Globe Health Inst Llc | Nanopartículas biodegradables y clínicamente compatibles como vehículos de suministro de fármacos. |
| AU2014248958A1 (en) | 2013-03-13 | 2015-10-01 | Monsanto Technology Llc | Methods and compositions for weed control |
| CA2905027A1 (en) | 2013-03-13 | 2014-10-09 | Monsanto Technology Llc | Methods and compositions for weed control |
| US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
| US20160030384A1 (en) | 2013-04-09 | 2016-02-04 | Boston Biomedical, Inc. | 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer |
| MX359191B (es) | 2013-07-19 | 2018-09-18 | Monsanto Technology Llc | Composiciones y métodos para controlar leptinotarsa. |
| AR098295A1 (es) | 2013-11-04 | 2016-05-26 | Monsanto Technology Llc | Composiciones y métodos para controlar infestaciones de plagas y parásitos de los artrópodos |
| JP6772062B2 (ja) | 2013-12-02 | 2020-10-21 | フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． | 癌の免疫療法 |
| UA119253C2 (uk) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Спосіб боротьби із вірусом у кліща varroa та у бджіл |
| WO2015099122A1 (ja) | 2013-12-26 | 2015-07-02 | 学校法人東京医科大学 | 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途 |
| SG10201805087VA (en) * | 2013-12-27 | 2018-07-30 | Bonac Corp | Artificial match-type mirna for controlling gene expression and use therefor |
| AU2015206585A1 (en) | 2014-01-15 | 2016-07-21 | Monsanto Technology Llc | Methods and compositions for weed control using EPSPS polynucleotides |
| US10125365B2 (en) | 2014-02-05 | 2018-11-13 | Yeda Research And Development Co. Ltd. | Micro-RNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions |
| TW201620525A (zh) * | 2014-03-14 | 2016-06-16 | 波士頓生醫公司 | 使ｋ－ｒａｓ靜默之非對稱干擾ｒｎａ組成物及其使用方法 |
| EP3420809A1 (en) | 2014-04-01 | 2019-01-02 | Monsanto Technology LLC | Compositions and methods for controlling insect pests |
| CA2947270A1 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic acids targeting mdm2 or mycn |
| EP3145550B1 (en) * | 2014-05-19 | 2019-03-27 | BioNTech AG | Particles comprising protamine and rna in combination with endosome destabilizing agents |
| KR101681669B1 (ko) * | 2014-05-27 | 2016-12-02 | 주식회사 제노포커스 | 유전자 침묵에 의한 목적 단백질의 과발현 방법 |
| US10988764B2 (en) | 2014-06-23 | 2021-04-27 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via RNA interference |
| EP3161138A4 (en) | 2014-06-25 | 2017-12-06 | Monsanto Technology LLC | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
| CN114009454A (zh) | 2014-07-29 | 2022-02-08 | 孟山都技术公司 | 用于控制昆虫害虫的组合物和方法 |
| EP3188799B1 (en) | 2014-09-05 | 2022-07-06 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1 |
| KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| CN114717264A (zh) | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| JP6637652B2 (ja) * | 2014-11-21 | 2020-01-29 | 株式会社バイオシンクタンク | 抗腫瘍剤の選択方法およびその抗腫瘍剤が含有するｓｉＲＮＡ |
| US10264976B2 (en) * | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
| US11045488B2 (en) | 2014-12-26 | 2021-06-29 | Nitto Denko Corporation | RNA interference agents for GST-π gene modulation |
| WO2016104775A1 (ja) | 2014-12-27 | 2016-06-30 | 株式会社ボナック | 遺伝子発現制御のための天然型ｍｉＲＮＡおよびその用途 |
| RU2723049C2 (ru) | 2015-01-22 | 2020-06-08 | Монсанто Текнолоджи Ллс | Композиции и способы борьбы с leptinotarsa |
| CN104673796A (zh) * | 2015-02-09 | 2015-06-03 | 暨南大学 | 靶向hsv-1病毒ul18基因的小干扰rna及应用 |
| EP3271464A4 (en) * | 2015-03-16 | 2018-10-31 | Miragen Therapeutics, Inc. | Mirna mimetics and their use in treating sensory conditions |
| JP6602847B2 (ja) | 2015-03-27 | 2019-11-06 | 株式会社ボナック | デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子 |
| EP3929293A3 (en) | 2015-04-03 | 2022-03-16 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| US10883103B2 (en) | 2015-06-02 | 2021-01-05 | Monsanto Technology Llc | Compositions and methods for delivery of a polynucleotide into a plant |
| US10655136B2 (en) | 2015-06-03 | 2020-05-19 | Monsanto Technology Llc | Methods and compositions for introducing nucleic acids into plants |
| WO2016196935A1 (en) | 2015-06-03 | 2016-12-08 | Boston Biomedical, Inc. | Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer |
| MX368314B (es) | 2015-06-05 | 2019-09-27 | Miragen Therapeutics Inc | Inhibidores del mir-155 para tratar linfoma cutáneo de células t (ctcl). |
| US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
| US11001845B2 (en) | 2015-07-06 | 2021-05-11 | Phio Pharmaceuticals Corp. | Nucleic acid molecules targeting superoxide dismutase 1 (SOD1) |
| WO2017030973A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| GB201516685D0 (en) * | 2015-09-21 | 2015-11-04 | Varghese Oommen P And Oommen Oommen P | Nucleic acid molecules with enhanced activity |
| US11021707B2 (en) | 2015-10-19 | 2021-06-01 | Phio Pharmaceuticals Corp. | Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA |
| JP7027311B2 (ja) | 2015-11-16 | 2022-03-01 | オリックス ファーマシューティカルズ，インコーポレーテッド | ＭｙＤ８８又はＴＬＲ３を標的とするＲＮＡ複合体を使用した加齢黄斑変性の治療 |
| WO2017100127A1 (en) | 2015-12-06 | 2017-06-15 | Boston Biomedical, Inc. | ASYMMETRIC INTERFERING RNAs, AND COMPOSITIONS, USE, OR PREPARATION THEREOF |
| AU2016371624B2 (en) | 2015-12-13 | 2020-08-27 | Nitto Denko Corporation | siRNA structures for high activity and reduced off target |
| WO2017132669A1 (en) | 2016-01-31 | 2017-08-03 | University Of Massachusetts | Branched oligonucleotides |
| WO2017134525A1 (en) | 2016-02-02 | 2017-08-10 | Olix Pharmaceuticals, Inc. | TREATMENT OF ATOPIC DERMATITIS AND ASTHMA USING RNA COMPLEXES THAT TARGET lL4Rα, TRPA1, OR F2RL1 |
| KR102825945B1 (ko) | 2016-02-02 | 2025-06-30 | 올릭스 주식회사 | Angpt2 및 pdgfb를 표적화하는 rna 복합체를 사용하는 혈관신생 관련 질환의 치료 |
| WO2017139758A1 (en) * | 2016-02-12 | 2017-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Rna/dna hybrid nanoparticles modified with single stranded rna toeholds and uses thereof |
| KR102775461B1 (ko) | 2016-04-01 | 2025-02-28 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩타이드 조성물 및 이의 용도 |
| JP7049262B2 (ja) | 2016-04-11 | 2022-04-06 | オリックス ファーマシューティカルズ，インコーポレーテッド | 結合組織成長因子を標的とするｒｎａ複合体を用いた特発性肺胞線維症の治療 |
| US10584337B2 (en) | 2016-05-18 | 2020-03-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| IL297576B2 (en) | 2016-05-18 | 2024-02-01 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
| WO2018005444A2 (en) | 2016-06-28 | 2018-01-04 | Boston Biomedical, Inc. | Methods for treating cancer |
| KR101916652B1 (ko) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
| CN107630015B (zh) | 2016-07-19 | 2021-03-09 | 上海市东方医院 | 一种稳定的dna-rna双链结构 |
| WO2018031933A2 (en) | 2016-08-12 | 2018-02-15 | University Of Massachusetts | Conjugated oligonucleotides |
| JP6842779B2 (ja) * | 2016-10-31 | 2021-03-17 | 国立大学法人岐阜大学 | 二本鎖核酸分子、およびその用途 |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| CA3045306A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| EP4410373A3 (en) * | 2017-01-31 | 2025-01-08 | Curigin Co.,Ltd. | Nucleic acid simultaneously inhibiting expression of mtor gene and stat3 gene |
| WO2018146557A2 (en) | 2017-02-10 | 2018-08-16 | Dong Ki Lee | Long double-stranded rna for rna interference |
| WO2018160887A1 (en) * | 2017-03-01 | 2018-09-07 | Boston Biomedical, Inc. | Pdl1-specific and beta-catenin-specific asymmetric interfering rna compositions, uses or preparation thereof |
| JP7167059B2 (ja) | 2017-04-19 | 2022-11-08 | フィオ ファーマシューティカルズ コーポレーション | 核酸化合物の局所送達 |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| MX2019013172A (es) | 2017-05-05 | 2020-09-07 | Voyager Therapeutics Inc | Composiciones y metodos para tratar la enfermedad de huntington. |
| JP2020520923A (ja) | 2017-05-17 | 2020-07-16 | ボストン バイオメディカル， インコーポレイテッド | がんを処置するための方法 |
| WO2018237245A1 (en) | 2017-06-23 | 2018-12-27 | University Of Massachusetts | TWO TAIL SELF-ADMINISTRATION SIRNA AND ASSOCIATED METHODS |
| JP6974872B2 (ja) * | 2017-06-30 | 2021-12-01 | 国立大学法人 東京医科歯科大学 | ヘテロ二本鎖型ａｎｔｉｍｉＲ |
| US12054711B2 (en) | 2017-07-14 | 2024-08-06 | City Of Hope | Meta-stable oligonucleotides junctions for delivery of therapeutics |
| WO2019033083A1 (en) | 2017-08-10 | 2019-02-14 | City Of Hope | CONDITIONAL RNAIDS AND THEIR USES IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA |
| CN111630166B (zh) | 2017-08-10 | 2024-04-19 | 希望之城 | 条件性-siRNA及其在治疗心肌肥大中的用途 |
| JP7208911B2 (ja) | 2017-10-11 | 2023-01-19 | 日東電工株式会社 | 核酸分子発現の調節 |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| KR102138495B1 (ko) * | 2017-11-27 | 2020-07-28 | (주)프로스테믹스 | 이중 가닥의 올리고뉴클레오티드 및 그 제조 방법 |
| CN118638787A (zh) | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| US12083143B2 (en) | 2018-04-06 | 2024-09-10 | University Of Massachusetts | MLK-regulated microRNAs in angiogenesis and tumor development |
| US20220110964A1 (en) * | 2018-08-03 | 2022-04-14 | Lemonex Inc. | Pharmaceutical composition for preventing or treating atopic diseases |
| BR112021002440A2 (pt) | 2018-08-10 | 2021-05-04 | University Of Massachusetts | oligonucleotídeos modificados visando snps |
| WO2020041769A1 (en) | 2018-08-23 | 2020-02-27 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| CA3118924A1 (en) | 2018-11-09 | 2020-05-14 | Ginkgo Bioworks, Inc. | Biosynthesis of mogrosides |
| KR102321425B1 (ko) * | 2019-01-18 | 2021-11-04 | 올릭스 주식회사 | NRL(Neural retina leucine zipper)의 발현을 억제하는 비대칭 siRNA |
| CN113614232A (zh) | 2019-01-18 | 2021-11-05 | 马萨诸塞大学 | 动态药代动力学修饰锚 |
| WO2020226960A1 (en) | 2019-05-03 | 2020-11-12 | Dicerna Pharmaceuticals, Inc. | Double-stranded nucleic acid inhibitor molecules with shortened sense strands |
| KR20220047989A (ko) | 2019-08-09 | 2022-04-19 | 유니버시티 오브 매사추세츠 | Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드 |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| TW202144572A (zh) | 2020-03-19 | 2021-12-01 | 美商亞維代堤生物科學公司 | 治療臉肩胛肱骨肌肉失養症之組合物及方法 |
| JP7723987B2 (ja) * | 2020-04-21 | 2025-08-15 | ユニバーシティ オブ マサチューセッツ | 加齢性黄斑変性を処置するための方法および組成物 |
| CA3174079A1 (en) | 2020-05-26 | 2021-12-02 | Anastasia Khvorova | Synthetic oligonucleotides having regions of block and cluster modifications |
| US20250034561A1 (en) | 2021-02-18 | 2025-01-30 | Oneglobe Holdings Limited | Novel Compositions for Conjugating Oligonucleotides and Carbohydrates |
| IL308337A (en) | 2021-05-13 | 2024-01-01 | Us Health | Preparations and methods for the treatment of sickle cell disease |
| EP4347829A1 (en) | 2021-05-29 | 2024-04-10 | 1Globe Health Institute LLC | Asymmetric short duplex dna as a novel gene silencing technology and use thereof |
| AU2022286925A1 (en) | 2021-05-29 | 2023-12-21 | 1Globe Health Institute Llc | Short duplex dna as a novel gene silencing technology and use thereof |
| IL309334A (en) | 2021-06-23 | 2024-02-01 | Univ Massachusetts | Anti-FLT1 optimized oligonucleotide compounds for the treatment of preeclampsia and other angiogenic disorders |
| US20240425853A1 (en) * | 2021-07-22 | 2024-12-26 | Microbio (Shanghai) Co. Ltd. | Modified small interfering rna molecules with reduced off-target effects |
| EP4401792A4 (en) | 2021-09-16 | 2025-12-03 | Avidity Biosciences Inc | COMPOSITIONS AND METHODS OF TREATMENT OF FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY |
| WO2023081500A2 (en) * | 2021-11-08 | 2023-05-11 | Dicerna Pharmaceuticals, Inc. | RNAi OLIGONUCLEOTIDE CONJUGATES |
| WO2023207615A1 (zh) * | 2022-04-26 | 2023-11-02 | 南京明德新药研发有限公司 | 一类含由天然核苷酸组成突出端的双链RNAi化合物 |
| WO2024040531A1 (en) | 2022-08-25 | 2024-02-29 | 1Globe Health Institute, Nanjing | Novel compositions for conjugating oligonucleotides and carbohydrates |
| JP2025542580A (ja) * | 2022-12-08 | 2025-12-26 | １グローブ ヘルス インスティテュート エルエルシー | 遺伝子サイレンシング技術としての、デオキシリボヌクレオチドが散在している短鎖二重鎖ｒｎａ、およびその使用 |
| WO2025049599A1 (en) | 2023-08-29 | 2025-03-06 | President And Fellows Of Harvard College | Methods for treating muscle-related disorders by modulating prolyl hydroxylase 3 |
| WO2025184876A1 (zh) * | 2024-03-07 | 2025-09-12 | 竣莅医药科技（无锡）有限公司 | 一种rna干扰触发分子与对应核酸干扰药物制剂及其用途 |
| CN118460650B (zh) * | 2024-07-10 | 2025-02-14 | 凯莱英医药集团（天津）股份有限公司 | 一种Nedosiran的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100523215C (zh) | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| US20070042983A1 (en) * | 2001-05-18 | 2007-02-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| US20060211642A1 (en) * | 2001-05-18 | 2006-09-21 | Sirna Therapeutics, Inc. | RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA) |
| US7074824B2 (en) | 2001-07-31 | 2006-07-11 | Arqule, Inc. | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| US6962944B2 (en) | 2001-07-31 | 2005-11-08 | Arqule, Inc. | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| EP2305813A3 (en) * | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US20040248299A1 (en) * | 2002-12-27 | 2004-12-09 | Sumedha Jayasena | RNA interference |
| WO2005056761A2 (en) * | 2003-12-05 | 2005-06-23 | Massachusetts Institute Of Technology | REAGENTS AND METHODS FOR IDENTIFICATION OF RNAi PATHWAY GENES AND CHEMICAL MODULATORS OF RNAi |
| US20060069050A1 (en) * | 2004-02-17 | 2006-03-30 | University Of Massachusetts | Methods and compositions for mediating gene silencing |
| US20050203047A1 (en) * | 2004-03-10 | 2005-09-15 | Ulrich Thomann | Delivery vectors for short interfering RNA, micro-RNA and antisense RNA |
| CA2559955C (en) * | 2004-03-15 | 2016-02-16 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
| US20060142228A1 (en) | 2004-12-23 | 2006-06-29 | Ambion, Inc. | Methods and compositions concerning siRNA's as mediators of RNA interference |
| EP3121281B1 (en) | 2007-08-27 | 2021-03-31 | 1Globe Health Institute LLC | Compositions of asymmetric interfering rna and uses thereof |
| KR100949791B1 (ko) * | 2007-12-18 | 2010-03-30 | 이동기 | 오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도 |
| TW201620525A (zh) | 2014-03-14 | 2016-06-16 | 波士頓生醫公司 | 使ｋ－ｒａｓ靜默之非對稱干擾ｒｎａ組成物及其使用方法 |
-
2008
- 2008-08-27 EP EP16187862.4A patent/EP3121281B1/en active Active
- 2008-08-27 DK DK08828867.5T patent/DK2193140T3/en active
- 2008-08-27 US US12/199,797 patent/US9328345B2/en active Active
- 2008-08-27 CN CN201510250692.XA patent/CN105018492B/zh active Active
- 2008-08-27 JP JP2010523120A patent/JP2010537639A/ja active Pending
- 2008-08-27 CA CA2735166A patent/CA2735166C/en active Active
- 2008-08-27 CN CN200880113323A patent/CN101842381A/zh active Pending
- 2008-08-27 EP EP21158616.9A patent/EP3889261A1/en active Pending
- 2008-08-27 US US12/675,620 patent/US20100286378A1/en not_active Abandoned
- 2008-08-27 WO PCT/US2008/074528 patent/WO2009029688A2/en not_active Ceased
- 2008-08-27 CN CN200880113236.9A patent/CN101835789B/zh active Active
- 2008-08-27 ES ES08828867.5T patent/ES2617877T3/es active Active
- 2008-08-27 WO PCT/US2008/074531 patent/WO2009029690A1/en not_active Ceased
- 2008-08-27 ES ES16187862T patent/ES2873350T3/es active Active
- 2008-08-27 CA CA2735167A patent/CA2735167A1/en not_active Abandoned
- 2008-08-27 EP EP08798830A patent/EP2201022A4/en not_active Withdrawn
- 2008-08-27 EP EP08828867.5A patent/EP2193140B1/en active Active
- 2008-08-27 JP JP2010523121A patent/JP2010537640A/ja active Pending
-
2014
- 2014-02-24 JP JP2014032700A patent/JP5986596B2/ja active Active
-
2015
- 2015-04-20 JP JP2015085681A patent/JP2015130885A/ja active Pending
-
2016
- 2016-03-25 US US15/081,559 patent/US10266821B2/en active Active
- 2016-06-07 JP JP2016113256A patent/JP6236498B2/ja active Active
- 2016-06-21 JP JP2016122512A patent/JP6453275B2/ja active Active
-
2017
- 2017-05-01 JP JP2017091309A patent/JP2017127333A/ja active Pending
-
2019
- 2019-02-20 US US16/280,830 patent/US10927376B2/en active Active
- 2019-03-11 US US16/298,545 patent/US11015195B2/en active Active
-
2021
- 2021-04-22 US US17/237,856 patent/US12344840B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6236498B2 (ja) | 非対称性干渉ｒｎａの組成物およびその使用 | |
| JP5986928B2 (ja) | 遺伝子発現の特異的阻害のためのダイサー基質剤及び方法 | |
| JP5855463B2 (ja) | 遺伝子発現の特異的阻害のための拡張ｄｉｃｅｒ基質薬剤および方法 | |
| US20220162608A1 (en) | Extended dicer substrate agents and methods for the specific inhibition of gene expression | |
| HK40051253A (en) | Compositions of asymmetric interfering rna and uses thereof | |
| HK1228948A1 (en) | Compositions of asymmetric interfering rna and uses thereof | |
| HK1228948B (en) | Compositions of asymmetric interfering rna and uses thereof | |
| HK1148534B (en) | Compositions of asymmetric interfering rna and uses thereof | |
| HK1217349B (en) | Compositions of asymmetric interfering rna and uses thereof | |
| HK1148535A (en) | Composition of asymmetric rna duplex as microrna mimetic or inhibitor |